RUA Life Sciences plc
RUA.L · LSE
3/31/2025 | 9/30/2024 | 3/31/2024 | 9/30/2023 | |
|---|---|---|---|---|
| Market Cap | £0 | £0 | £0 | £0 |
| - Cash | £0 | £0 | £0 | £0 |
| + Debt | £0 | £0 | £0 | £0 |
| Enterprise Value | £0 | £0 | -£0 | £0 |
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | 69.9% | 9.1% | 75.9% | – |
| Gross Profit | £0 | £0 | £0 | £0 |
| % Margin | 73.5% | 71.6% | 78.7% | 54.3% |
| EBITDA | -£0 | £0 | -£0 | -£0 |
| % Margin | -17.1% | 55.3% | -28.5% | -148% |
| Net Income | -£0 | £0 | -£0 | -£0 |
| % Margin | -24.5% | 41.7% | -30.8% | -127.2% |
| EPS Diluted | -0.01 | 0.019 | -0.013 | -0.046 |
| % Growth | -154% | 247.7% | 71.9% | – |
| Operating Cash Flow | £0 | -£0 | -£0 | -£0 |
| Capital Expenditures | -£0 | -£0 | -£0 | -£0 |
| Free Cash Flow | -£0 | -£0 | -£0 | -£0 |